The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma

Blood Cancer Journal · Published 2026-07-11 · DOI 10.1038/s41408-026-01575-y

Free full text

Authors (14)

Jiadai Xu, Jing Li, Yuhong Ren, Luya Cheng, Zhixiang Cheng, Jingli Zhuang, Yang Ke, Shiyang Gu, Yian Zhang, Feifei Chen, Rupan Gao, Panpan Li, Yaqin Xiong, Peng Liu

Abstract

DOAJ holds no abstract for this record.

Read the article at the publisher →

Publication details

Year

2026

Citation

Xu, J., Li, J., Ren, Y., et al. (2026). The efficacy, safety, and rationale of orelabrutinib combined with obinutuzumab (O2) as a first-line systemic treatment for marginal zone lymphoma. Blood Cancer Journal. https://doi.org/10.1038/s41408-026-01575-y

Related articles

• Long-term follow-up of the transplant-eligible cohort of the EMN12/HOVON-129 study for primary plasma cell leukemia patients · Blood Cancer Journal · 2026 · Same journal
• Prospective phase II study of frontline Helicobacter pylori eradication therapy for early-stage extragastric mucosa-associated lymphoid tissue lymphoma · Blood Cancer Journal · 2026 · Same journal
• Fixed-dose inotuzumab ozogamicin (INO) combined with Vincristine and Prednisone (VP) regimen as induction therapy for newly diagnosed B-cell acute lymphocytic leukemia (B-ALL): a multi-center, open-label, single-arm, prospective clinical study · Blood Cancer Journal · 2026 · Same journal
• Linvoseltamab outcomes by frailty status in patients with relapsed/refractory multiple myeloma: a subgroup analysis of the LINKER-MM1 study · Blood Cancer Journal · 2026 · Same journal
• Response profile and long-term outcomes in Cyclin D1-overexpressing multiple myeloma: insights from the CASSIOPEIA trial · Blood Cancer Journal · 2026 · Same journal
• Preclinical and clinical efficacy of the HDAC6 inhibitor ricolinostat in combination with BCR pathway inhibitors in relapsed/refractory chronic lymphocytic leukemia · Blood Cancer Journal · 2026 · Same journal
• Venetoclax, azacitidine, and G-CSF targeting molecular residual disease in CBFB::MYH11 AML resistant to high-dose cytarabine · Blood Cancer Journal · 2026 · Same journal
• Long-term clinical outcomes from the smart start trial: rituximab, lenalidomide and ibrutinib in patients with newly diagnosed large B-cell lymphoma · Blood Cancer Journal · 2026 · Same journal
• Outcomes of patients with relapsed or refractory classic Hodgkin lymphoma after frontline brentuximab vedotin · Blood Cancer Journal · 2026 · Same journal
• Arterial thrombosis and cancer: insights from observations in myeloproliferative neoplasms and CHIP · Blood Cancer Journal · 2026 · Same journal